Welcome to the BMT SIG Virtual Community

On this SIG Virtual Community page, you will find information pertaining the Blood and Marrow Stem Cell Transplant SIG. Here, you can view myriad resources, download and complete pertinent documents, join in our discussions and much more. Welcome to our SIG Virtual Community.

Blood and Marrow SIG Mission

To promote excellend in BMSCT nrusing by:

• Establishing the highest professional standards
• Studying, researching, and exchanging standards
• Encouraging nurses to specialize in the practice area
• Foster professional development, individually and collectively
• Maintaining an organizational structuer and function that is responsive to the changing needs of members and the patients they represent

SIG goals for 2009-1012

1. To provide an expert voice for oncology BMSCT nursing practice and research.
   • Nominate colleagues for the Josh Gottheil Career Development Award
   • Utilize the virtual community to share practice and research initiatives.
2. To provide professional development through participation in the online BMSCT course and Tandem BMT and ONS meetings and publications.
   • To develop and implement a standardized BMSCT curriculum and online BMSCT course.
   • To develop and implement a national certification in the field of blood and marrow transplant nursing.
3. To partner with professional organizations and other entities to address care needs of BMSCT patients and SIG members.
   • Collaborate with the NMDP on the System Capacity Initiative to address the nursing workforce impact on BMSCT.
   • Partner with the European Blood and Marrow Transplant Nursing Group
   • Use regional reporter structure to support and encourage collaboration in different geographical areas

Ofatumumab Application to FDA for the Treatment of Advanced Stage Blood Cancer 

The Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions
The Centers for Medicare and Medicaid Services is seeking public comment on their proposed determination that there is sufficient evidence to conclude that erythropoiesis stimulating agent (ESA) treatment is not reasonable and necessary for beneficiaries with certain clinical conditions, either because of a deleterious effect of the ESA on their underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use. Click here to read more of CMS proposed decision.

Commentary on the CMS Proposed Ruling from Other Organizations

BMSCT Nursing Resource Directory

The directory contains a comprehensive overview of the demographics of national and international blood and marrow transplant programs, including contacts.

The BMSCT Nursing Resource Directory is currently undergoing construction. When it is complete, a link will be added to this site. In the meantime, if you have changes to your current information or would like to add your institution to the directory, please print out and complete the data sheet and send to the address/fax number provided. If you have any questions, please e-mail jholmes@ons.org.